Armitage J O, Klassen L W, Patil S R, Kugler J W, Gingrich R D, Ahmann G B, Fyfe M A, Tewfik H H
Exp Hematol. 1984 Oct;12(9):717-9.
Ten patients with chronic granulocytic leukemia in the stable phase underwent marrow transplantation from HLA-identical siblings (nine cases) or an identical twin (one case) following preparation with cytarabine, cyclophosphamide, and total body irradiation. Marrow cytogenetics on all patients prior to transplantation revealed the Philadelphia chromosome without other evidence of aneuploidy. The immediate posttransplant course was in most cases relatively uncomplicated with only two serious infections and one death. All patients recovered with cytogentically normal marrow and leukemia has recurred only in the syngeneic transplant recipient. At present, nine patients are surviving from 358 to 961 days (median 597 days) after bone marrow transplantation. Bone marrow transplantation is capable of eliminating the abnormal clone of myeloid cells in patients with stable-phase chronic granulocytic leukemia and can be performed relatively safely in this "healthy" group of patients.
10例处于稳定期的慢性粒细胞白血病患者在接受阿糖胞苷、环磷酰胺及全身照射预处理后,接受了来自HLA相同同胞(9例)或同卵双胞胎(1例)的骨髓移植。所有患者移植前的骨髓细胞遗传学检查均显示费城染色体,无其他非整倍体证据。大多数患者移植后的近期病程相对平稳,仅发生2例严重感染和1例死亡。所有患者均获得细胞遗传学正常的骨髓恢复,仅同基因移植受者白血病复发。目前,9例患者在骨髓移植后存活358至961天(中位值597天)。骨髓移植能够清除稳定期慢性粒细胞白血病患者骨髓中的异常髓系细胞克隆,并且在这群“健康”患者中能够相对安全地进行。